



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2012-002637-11/ Novartis Protocol ID CFTY720DDE19

*A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis*

Trial CFTY720DDE19 was cancelled with no patient enrollment and as such, no results will be reported.